Comparative Pharmacology
Head-to-head clinical analysis: EPHEDRINE SULFATE versus VASOXYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPHEDRINE SULFATE versus VASOXYL.
EPHEDRINE SULFATE vs VASOXYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ephedrine sulfate is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors and indirectly stimulates norepinephrine release from sympathetic neurons, leading to vasoconstriction, bronchodilation, and increased heart rate and contractility.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction and increased blood pressure.
50 mg orally every 3-4 hours as needed; 25-50 mg intramuscularly or subcutaneously every 3-4 hours; 5-25 mg intravenously slowly every 5-10 minutes as needed, not to exceed 150 mg in 24 hours.
Intravenous bolus: 0.1-0.2 mg per dose; intravenous infusion: 0.1-0.2 mg/min; intramuscular or subcutaneous: 0.5-1 mg per dose.
None Documented
None Documented
Terminal elimination half-life 3-6 hours in adults with normal renal function; prolonged in renal impairment or alkaline urine.
Terminal elimination half-life is 2.5-3.0 hours; clinically relevant for dosing intervals in hypotension management.
Renal excretion of unchanged drug (60-70%) and minor metabolites; small amount biliary; pH-dependent; acidic urine enhances elimination.
Primarily renal excretion as unchanged drug and metabolites (phenylephrine is deaminated by MAO). Approximately 80-85% excreted in urine within 24 hours; negligible biliary/fecal elimination.
Category C
Category C
Vasopressor
Vasopressor